AgomAb Therapeutics NV (AGMB) Stock Price, News & Analysis
Company Description
Agomab Therapeutics NV (AGMB) develops disease-modifying therapeutics for fibro-inflammatory, immunology, and inflammatory diseases. The company is a clinical-stage biopharmaceutical issuer headquartered in Antwerp, Belgium, and its American Depositary Shares trade on the Nasdaq Global Select Market under the symbol AGMB. Each ADS represents one common share of Agomab.
Agomab's research and development model centers on chronic fibrotic indications and therapies designed to target established biological pathways. Its product candidates use small-molecule and antibody approaches, including organ-restricted strategies intended to focus activity in affected tissues. The company describes its program focus as resolving fibro-inflammation and restoring organ function in diseases associated with fibrosis.
The company's disclosed pipeline includes ontunisertib, also known as AGMB-129, and AGMB-447. Ontunisertib is being developed in fibrostenosing Crohn's disease, a fibrotic complication of inflammatory bowel disease. AGMB-447 is an investigational inhaled, lung-restricted small molecule inhibitor of ALK5, also referred to as TGFβR1, in development for idiopathic pulmonary fibrosis. Agomab has reported U.S. composition-of-matter patent coverage for AGMB-447.
As a development-stage biopharmaceutical company, Agomab's operating activity is focused on pre-commercial research and clinical development rather than commercial product sales. Its recurring corporate disclosures address clinical-program progress, intellectual-property protection, regulatory interactions, research and development spending, financing activity, and governance matters. Agomab completed its initial public offering of ADSs in February 2026, establishing AGMB as a publicly traded foreign private issuer in the United States.
Stock Performance
AgomAb Therapeutics NV (AGMB) stock last closed at $12.51. At a market capitalization of $616.1M, AGMB is classified as a small-cap stock with approximately 49.2M shares outstanding.
AGMB Rankings
Latest News
AgomAb Therapeutics NV has 7 recent news articles. Of the recent coverage, 3 articles coincided with positive price movement and 3 with negative movement. Key topics include earnings, IPO, offering. View all AGMB news →
SEC Filings
AgomAb Therapeutics NV has filed 5 recent SEC filings, including 3 Form SCHEDULE 13G, 2 Form 6-K. The most recent filing was submitted on June 23, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all AGMB SEC filings →
Financial Highlights
Upcoming Events
Phase 1b patient results
AgomAb Therapeutics NV has 1 upcoming scheduled event. The next event, "Phase 1b patient results", is scheduled for September 1, 2026 (in 34 days). Investors can track these dates to stay informed about potential catalysts that may affect the AGMB stock price.
Short Interest History
Short interest in AgomAb Therapeutics NV (AGMB) currently stands at 1.2 million shares, down 0.1% from the previous reporting period, representing 2.7% of the float. Since February 2026, short interest has increased by 952.1%. This relatively low short interest suggests limited bearish sentiment. With 14.6 days to cover, it would take significant time for short sellers to close their positions based on average trading volume.
Days to Cover History
Days to cover for AgomAb Therapeutics NV (AGMB) currently stands at 14.6 days, up 66.5% from the previous period. This elevated days-to-cover ratio indicates it would take over two weeks of average trading volume for short sellers to exit their positions, suggesting potential for a short squeeze if positive news emerges. The days to cover has increased 1355% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 1.0 to 18.4 days.
AGMB Company Profile & Sector Positioning
AgomAb Therapeutics NV (AGMB) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ. In monthly performance, the stock ranks #650 among all tracked companies.